Gadoquatrane

Gadoquatrane
Clinical data
Trade names	Ambelvist
License data	US DailyMed: Gadoquatrane;
Routes of; administration	Intravenous
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name rac-[{μ4-2,2',2'',2''',2'''',2'''''-[{(2R,16Ξ)-3,6,12,15-tetraoxo-1κO3:2κO15-9,9-bis[(2-{(2Ξ)-2-[4,7,10-tris(carboxy-3κ3O4,O7,O10:4κ3O4',O7',O10'-methyl)-1,4,7,10-tetraazacyclododecan-1-yl-3κ4N1,N4,N7,N10:4κ4N1',N4',N7',N10']-propanamido-3κO:4κO'}acetamido)methyl]-4,7,11,14-tetraazaheptadecane-2,16-diyl}bis(1,4,7,10-tetraazacyclododecane-10,1,4,7-tetrayl-1κ4N1,N4,N7,N10:2κ4N1',N4',N7',N10')]hexaacetato-1κ3O1,O4,O7:-2κ3O1',O4',O7'}(12−)]tetragadolinium;
CAS Number	2048221-65-2;
ChemSpider	129957893;
UNII	OZG7J613HK;
ChEMBL	ChEMBL6068450;
Chemical and physical data
Formula	C81H128Gd4N24O32
Molar mass	2579.05 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)NCC(=O)NCC(CNC(=O)CNC(=O)C(C)N1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])(CNC(=O)CNC(=O)C(C)N2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CNC(=O)CNC(=O)C(C)N3CCN(CCN(CCN(CC3)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N4CCN(CCN(CCN(CC4)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Gd+3].[Gd+3].[Gd+3];
	InChI InChI=InChI=1S/C81H140N24O32.4Gd/c1-57(102-29-21-94(45-69(118)119)13-5-90(41-65(110)111)6-14-95(22-30-102)46-70(120)121)77(134)82-37-61(106)86-53-81(54-87-62(107)38-83-78(135)58(2)103-31-23-96(47-71(122)123)15-7-91(42-66(112)113)8-16-97(24-32-103)48-72(124)125,55-88-63(108)39-84-79(136)59(3)104-33-25-98(49-73(126)127)17-9-92(43-67(114)115)10-18-99(26-34-104)50-74(128)129)56-89-64(109)40-85-80(137)60(4)105-35-27-100(51-75(130)131)19-11-93(44-68(116)117)12-20-101(28-36-105)52-76(132)133;;;;/h57-60H,5-56H2,1-4H3,(H,82,134)(H,83,135)(H,84,136)(H,85,137)(H,86,106)(H,87,107)(H,88,108)(H,89,109)(H,110,111)(H,112,113)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,122,123)(H,124,125)(H,126,127)(H,128,129)(H,130,131)(H,132,133);;;;/q;4*+3/p-12; Key:HGIZCBUSWUYZEQ-UHFFFAOYSA-B;

Gadoquatrane, sold under the brand name Ambelvist, is a macrocylic gadolinium-based MRI contrast agent (mGBCA) that is used with contrast-enhanced magnetic resonance imaging (CE-MRI)^[2] to detect and visualize lesions with abnormal vascularity in certain parts of the body.^[3] Ambelvist is administered as an intravenous injection.

Medical uses

Ambelvist is indicated in people for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:^[3]^[1]

the central nervous system (brain, spine, and associated tissues)
the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system)

Society and culture

Legal status

Ambelvist was approved for medical use in the United States in June 2026.^[4]

Names

Gadoquatrane is the international nonproprietary name.^[5]

Gadoquatrane is sold under the brand name Ambelvist.^[1]

References

1 2 3 "DailyMed - Ambelvist- gadoquatrane injection". dailymed.nlm.nih.gov. Retrieved 28 June 2026.
↑ Frenzel T, Wels T, Pietsch H, Schöckel L, Seidensticker P, Endrikat J (March 2026). "Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media". Investigative Radiology. 61 (3): 214–223. doi:10.1097/RLI.0000000000001180. PMC 12871431. PMID 40163898.
1 2 "Ambelvist". Bayer Radiological Solutions.
↑ "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 26 June 2026.
↑ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.

[Ambelvist_FDA_label-1] 1 2 3 "DailyMed - Ambelvist- gadoquatrane injection". dailymed.nlm.nih.gov. Retrieved 28 June 2026.

[Frenzel_2026-2] Frenzel T, Wels T, Pietsch H, Schöckel L, Seidensticker P, Endrikat J (March 2026). "Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media". Investigative Radiology. 61 (3): 214–223. doi:10.1097/RLI.0000000000001180. PMC 12871431. PMID 40163898.

[Ambelvist_Bayer_Radiological-3] 1 2 "Ambelvist". Bayer Radiological Solutions.

[4] "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 26 June 2026.

[5] World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.

[1]

[2]

[3]

[4]

[5]